ArticleBMC cancer2013

Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.

Jun Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.